Pfizer (PFE) Stock Price Forecast: 2026, 2027, 2028–2030 and Beyond

Pfizer (#PFE) stocks have garnered considerable attention from investors thanks to their promising upside potential and highly active market conditions. Amid global economic volatility and new healthcare challenges, #PFE offers a compelling option for both short- and long-term investments.

Forecasts for the coming years show a wide range of potential prices, reflecting possible fluctuations and yield increases. Analyzing current trends and seasonal movements presents a unique opportunity to identify optimal market entry points and assess investment risk. 

This article provides an in-depth analysis of Pfizer stocks, helping you grasp the intricacies of the market and empowering you to make more informed trading decisions.

The article covers the following subjects:

Major Takeaways

• The PFE stock price is trading at $26.78 as of 05.02.2026.
• The PFE price reached its all-time high of $61.25 on 16.12.2021. The stock’s all-time low of $0.43 was recorded on 04.10.1974.
• In 2024, the company implemented strategic initiatives to optimize its product lineup and expand its global footprint.
• The PFE stock is traded on the New York Stock Exchange (NYSE) under the ticker symbol #PFE, making it accessible to a wide range of investors.
• The company maintains stable operating profit by actively investing in research and innovation.
• Free cash flow makes it possible to finance new projects and maintain a proper dividend policy.
• Experts predict that the Pfizer price may reach $37.94–$44.54 in 2026. However, some analysts anticipate a decline to $20.24–$26.76.
• Forecasts for 2027 also vary. A favorable scenario indicates that the PFE price will reach $39.51–$44.08, while a negative one suggests that the asset will decrease to $14.72.
• From 2028 to 2030, the price trajectory is expected to be uneven. Some experts predict an increase to $31.70, while others anticipate a drop to $13.74–$8.03.
• Long-term forecasts for the PFE stock performance between  2040 and 2050 are optimistic. Analysts are confident that Pfizer’s stock price will climb to $43.71 by 2037.

Pfizer (PFE) Real-Time Market Status

The current Pfizer (#PFE) stock price is $26.78 as of 05.02.2026.

Investors should monitor key metrics that help assess the financial strength of a company, upside potential, and stock liquidity. For example, market capitalization indicates the overall value of the company, while trading volume reflects market activity. The P/E ratio assesses stock profitability, and the price change over the last 12 months helps to assess the stock’s performance. Additionally, dividend yield and maximum supply help gauge shares’ profitability and availability.

Metric	Value
Market cap	$146.5 billion
Trading volume	52.4 million shares
P/E ratio	19.6
All-time high	$61.25
Price change over the last 12 months	9.1%
Dividends	$1.72
Shares outstanding	5.69 billion shares

Pfizer (PFE) Stock Price Forecast for 2026 Based on Technical Analysis

Let’s conduct a technical analysis of the weekly PFE chart to forecast the long-term movement of the stock price.

Since the beginning of 2026, Pfizer shares have been trading in a narrow price range of $24.82–$26.82. Technical indicators and candlestick patterns are giving mixed signals:

• A large Ascending Triangle (1) is forming on the chart. The price is expected to break above the pattern at $27.47, targeting $33.26 and higher. Inverted Hammer (2) and Hammer (3) reversal candlestick patterns have emerged near the key support level of $24.74, signaling a potential bullish reversal.
• MACD values are moving sideways near the zero line, confirming that the price is consolidating.
• The RSI reading is holding at 53, indicating that the price may either rise or fall.
• The MFI is increasing, showing an influx of liquidity into the asset. Tick volumes are also rising.
• The VWAP indicator and the SMA20 line are near the market price, suggesting a balance between bulls and bears.

Below are the #PFE share price estimates for the next 12 months.

Month	Minimum, $	Maximum, $
February 2026	25.22	27.33
March 2026	26.99	28.97
April 2026	28.22	30.54
May 2026	27.47	31.01
June 2026	27.27	30.40
July 2026	29.72	32.86
August 2026	30.20	33.67
September 2026	29.92	34.29
October 2026	33.67	36.81
November 2026	33.33	36.94
December 2026	32.86	38.58
January 2027	35.92	41.24

Long-Term Trading Plan for #PFE for 2026

The technical analysis conducted has revealed key support and resistance levels that can be used in a trading strategy for the coming year.

Trading Plan for the Year

• The price is expected to break above the Ascending Triangle over the next 1–2 months, possibly reaching $30.40–$33.26.
• Key support levels: $24.74, $22.03, $19.94, $17.05, $14.08, and $11.90.
• Key resistance levels: $27.47, $30.40, $33.26, $36.54, $38.92, $41.17, $43.97, and $46.56.
• Base scenario: Opening long trades above the key resistance level of $27.47 with potential targets in the $30.40–$46.56 range.
• Alternative scenario: Open short trades below the key support level of $24.74 with potential targets in the $22.03–$11.90 range.

Analysts’ PFE Share Price Projections for 2026

Analysts predict that PFE will grow moderately in 2026 amid the expected increase in the company’s revenue and the ongoing share buyback program. The consensus forecast among analysts is for prices to range between $37.94 and $44.54.

LongForecast

Price range: $24.28–$44.54.

LongForecast expects PFE’s share price to stabilize at $28.07 by the end of February 2026, rising to $31.96 by the summer and $41.24 by the end of December.

Month	Open, $	Min–Max, $	Close, $
February	26.44	24.28–30.32	28.07
March	28.07	25.61–32.18	29.8
April	29.8	29.11–34.17	31.64
May	31.64	28.69–33.67	31.18
June	31.18	29.40–34.52	31.96
July	31.96	30.09–35.33	32.71
August	32.71	32.71–38.83	35.95
September	35.95	34.90–40.96	37.93
October	37.93	35.44–41.60	38.52
November	38.52	37.78–44.34	41.06
December	41.06	37.94–44.54	41.24

WalletInvestor

Price range: $20.18–$27.26.

According to WalletInvestor, share prices may slide to $24.71 by the end of February, to $22.47 by mid-year, and to $20.24 in December.

Month	Open, $	Close, $	Minimum, $	Maximum, $
February	26.48	24.71	24.71	27.26
March	24.71	24.68	24.5	24.71
April	24.7	23.87	23.87	24.7
May	23.9	23.56	23.53	23.9
June	23.48	22.47	22.47	23.48
July	22.5	22.68	22.46	22.8
August	22.6	21.67	21.67	22.6
September	21.63	20.75	20.75	21.63
October	20.68	20.34	20.3	20.69
November	20.31	20.39	20.18	20.39
December	20.41	20.24	20.24	20.55

CoinCodex

Price range: $21.80–$28.56.

CoinCodex predicts that the PFE stock will see mixed performance in 2026. The asset is expected to reach $26.26 by summer and settle at $26.76 by December.

Month	Minimum, $	Average, $	Maximum, $
February	24.02	25.56	27.48
March	24.65	26.72	28.27
April	25.02	26.57	28.56
May	25.21	26.44	28.14
June	24.48	26.26	27.91
July	26.04	26.74	27.65
August	23.71	25.19	25.82
September	22.82	23.59	24.85
October	21.8	22.87	24.44
November	24.23	24.94	25.67
December	25.94	26.76	27.96

Analysts’ PFE Share Price Projections for 2027

Experts believe the clinical trial results for key drugs and the broader macroeconomic environment will affect PFE’s value in 2027. Optimistic estimates suggest the stock could rise to $39.51–$44.08. However, analysts do not rule out a decline to $14.72.

Note: The price ranges reflect the asset's expected volatility throughout the year. Lows and highs may not be shown in the summary tables.

LongForecast

Price range: $36.44–$48.56.

LongForecast predicts that the price will open 2027 at $41.24, range between $38.19 and $47.00 in the first half of the year, and close December at $44.08.

Quarter	Open, $	Min–Max, $	Close, $
Q1	41.24	38.19–45.67	42.29
Q2	42.29	38.91–47.00	43.52
Q3	43.52	36.44–46.04	39.61
Q4	39.61	39.23–48.56	44.08

StockScan

Price range: $29.60–$50.54.

According to StockScan, the average PFE price may reach $48.29 at the beginning of the year. The asset is projected to fluctuate significantly, falling to $39.51 by December.

Quarter	Average, $	Minimum, $	Maximum, $
Q1	48.29	29.60	50.24
Q2	37.66	34.38	50.54
Q3	43.12	35.49	45.44
Q4	39.51	35.55	43.81

CoinCodex

Price range: $13.68–$26.49.

CoinCodex assumes that the asset will reach $20.89 by the end of Q1, drop to $19.97 by the summer, and plunge to $14.72 by year-end.

Quarter	Minimum, $	Average, $	Maximum, $
Q1	20.53	20.89	26.49
Q2	18.72	19.97	21.69
Q3	16.58	17.55	19.46
Q4	13.68	14.72	17.55

Analysts’ PFE Share Price Projections for 2028

Experts are offering cautious forecasts for 2028 due to strong competition in the biopharmaceutical sector. The consensus forecast suggests that the price will range between $26.88 and $52.02.

LongForecast

Price range: $39.04–$56.22.

LongForecast anticipates that the Pfizer price will trade at $44.08 in early 2028, rise to $49.35 by September, and reach $52.02 by the end of December.

Quarter	Open, $	Min–Max, $	Close, $
Q1	44.08	39.04–49.63	42.44
Q2	42.44	42.44–53.00	48.35
Q3	48.35	41.32–53.54	49.35
Q4	49.35	44.90–56.22	52.02

StockScan

Price range: $25.96–$44.65.

StockScan forecasts that the price will open at $36.15, decline to $34.91 by the summer, and plummet to $26.88 by year-end.

Quarter	Average, $	Minimum, $	Maximum, $
Q1	36.15	31.00	39.60
Q2	34.91	34.44	44.65
Q3	31.50	29.17	35.14
Q4	26.88	25.96	32.00

CoinCodex

Price range: $12.89–$15.96.

According to CoinCodex, the average PFE price will reach $14.23 by the end of Q1, stabilize at $14.59 by June, and then slide to $13.43 by December.

Quarter	Minimum, $	Average, $	Maximum, $
Q1	13.45	14.23	15.49
Q2	13.16	14.59	15.27
Q3	14.31	15.14	15.96
Q4	12.89	13.43	15.46

Analysts’ PFE Share Price Projections for 2029

The PFE stock price will likely depend on the company’s ability to expand into new markets and broaden its product line by 2029. Optimistic projections suggest that the asset may advance to $44.95. However, the price may also decrease to $13.22–$13.69 by the end of the year.

LongForecast

Price range: $36.43–$55.20.

LongForecast projects that the stock price will be at $52.02 early in the year. A bearish trend is expected. The price may fall to $46.62 by the summer and to $44.95 by December.

Quarter	Open, $	Min–Max, $	Close, $
Q1	52.02	42.54–55.20	46.24
Q2	46.24	42.38–50.35	46.62
Q3	46.62	38.75–46.99	42.12
Q4	42.12	36.43–48.55	44.95

StockScan

Price range: $12.93–$28.06.

StockScan predicts a decline in PFE’s share price. The asset is expected to reach $24.46 at the beginning of the year, plummet to $18.55 by autumn, and close at $13.69.

Quarter	Average, $	Minimum, $	Maximum, $
Q1	24.46	23.93	28.06
Q2	19.50	18.89	24.55
Q3	18.55	16.38	20.95
Q4	13.69	12.93	19.54

CoinCodex

Price range: $11.23–$14.16.

According to CoinCodex estimates, the price of the Pfizer stock will average at $13.44 by the end of Q1, then drop to $12.46 and recover to $13.22 by the end of December.

Quarter	Minimum, $	Average, $	Maximum, $
Q1	12.96	13.44	14.10
Q2	11.23	12.46	12.92
Q3	12.13	12.61	13.40
Q4	12.64	13.22	14.16

Analysts’ PFE Share Price Projections for 2030

According to experts, PFE’s share price in 2030 will be determined by the growth of revenue from innovative drugs and investments in research and development. Some analysts suggest that the price may reach $31.70, while others anticipate a decline to $13.74–$8.03.

StockScan

Price range: $2.43–$17.83.

StockScan believes that the average price will be around $11.57 at the start of the year. The asset is predicted to slip to $10.66 by the summer before rebounding. Eventually, the stock price is expected to rise to $13.84 in Q3 and to $15.25 by year-end. The stock is prone to sharp declines.

Quarter	Average, $	Minimum, $	Maximum, $
Q1	11.57	11.10	17.83
Q2	10.66	7.46	12.00
Q3	13.60	10.24	13.84
Q4	8.03	2.43	15.25

CoinCodex

Price range: $11.20–$14.67.

According to CoinCodex, PFE shares will trade at $13.73 by the end of Q1, go down to $13.49 by mid-year, and slide to $12.96 by December.

Quarter	Minimum, $	Average, $	Maximum, $
Q1	12.34	13.73	14.52
Q2	12.58	13.49	14.67
Q3	11.72	12.12	14.20
Q4	11.20	12.96	14.36

CoinPriceForecast

Price range: $30.83–$31.70.

CoinPriceForecast expects a bullish trend, with the average price starting the year at $30.83, rising to $31.32 by summer, and ending at $31.70.

Year	Open, $	Mid-Year, $	Close, $
2030	30.83	31.32	31.70

Analysts’ PFE Share Price Projections until 2050

It is challenging to predict the performance of Pfizer’s stock price through 2050, and most experts avoid such long-term assessments. The pharmaceutical sector is highly volatile and influenced by numerous factors, including technological advances in medicine, changes in healthcare legislation, the emergence of new competitors, clinical trial results, and the development of new drugs.

However, expert estimates of the PFE price movement through 2050 can be used to assess potential risks and opportunities and to develop a more reliable long-term strategy.

CoinPriceForecast provides an upbeat outlook, predicting that the price will rise to $39.60 by 2035 and reach $43.71 by 2037.

According to Stockscan, the stock will trade in a long-term bearish trend, reaching $12.47 by 2035 and $9.02 by 2040.

Year	CoinPriceForecast, $	StockScan, $
2031	33.29	–
2033	36.19	–
2035	39.60	12.47
2037	43.71	–
2040	–	9.02

Market Sentiment for Pfizer (PFE) on Social Media

Media sentiment reflects the collective opinion of investors expressed across various social media platforms. Positive posts typically bolster PFE’s share price, while negative sentiment can trigger declines due to large-scale sell-offs.

User @TheLongInvest forecasts PFE to grow to $31.00.

Independent trader @Market1Surgeon predicts PFE shares to reach at least $32.00 by the end of 2026.

Independent expert @TBeit07 projects an increase to $32.00–$33.00.

Most investors and traders anticipate that the PFE price will climb. However, it is crucial to conduct technical and fundamental analysis and study market data before making any trading decisions.

Pfizer (PFE) Price History

Pfizer reached the highest price of $61.25 on 16.12.2021. The lowest price of Pfizer was recorded on 04.10.1974 when the stock declined to $0.43.

The chart below shows the #PFE price performance over the last ten years. It is crucial to evaluate historical data to make our forecasts as accurate as possible.

Pfizer’s share price has hit several key milestones since the early 2000s:

• In 2000, the #PFE price hit a record high of about $50, bolstered by the successful launch of blockbuster drugs such as Viagra, Lipitor, and Zoloft.
• From 2004 to 2009, the #PFE price plunged to $12–$15 due to the company losing several patents and facing heightened competition. Moreover, the global financial crisis of 2008 contributed to these challenges.
• From 2013 to 2019, Pfizer’s share price stabilized in the $35–$45 range thanks to advances in oncology, vaccines, biopharmaceuticals, and a solid dividend policy.
• In 2021, the asset set an all-time high of $61 as sales of Comirnaty, a vaccine developed with BioNTech, generated record revenue for the company.
• In 2023–2025, demand for the vaccine dropped sharply, consequently reducing revenue, and the #PFE price plummeted to $25–$30.
• In 2025, Pfizer shares remained confined to a narrow range of $20.91–$27.69 as sales of several drugs slowed.
• In January 2026, PFE shares consolidated between $24.82 and $26.82 as investors awaited the company’s new earnings reports.

The Pfizer stock has historically demonstrated the capacity to recover from severe downturns, indicating future upside potential.

Pfizer (PFE) Fundamental Analysis

Fundamental analysis plays a key role in forecasting the price of any asset. It involves assessing financial data, the company’s market position, and other indicators affecting the #PFE rate.

What Factors Affect the Pfizer (PFE) Stock?

• Financials. The company’s revenues, net income, profitability, and cash flows.
• Development and market launch of new drugs. Successful clinical tests and regulatory approvals.
• Patent protection. Expiration of patents on key drugs, the emergence of generics.
• Mergers and acquisitions. Strategic deals that expand product range and distribution markets.
• Regulatory environment. Changes in healthcare legislation and policy.
• Global economic conditions. Economic crises, currency fluctuations, and geopolitical instability.
• Competition. Actions of major competitors and innovation in the industry.
• Reputational risks. Lawsuits, fines, and public opinion.
• Dividend policy. Changes in the amount and regularity of payments to shareholders.
• Investor sentiment. General trends in the stock market and investors’ attitudes to the pharmaceutical sector.

Given these factors, investors can objectively assess the prospects of the Pfizer stock and make more informed decisions.

More Facts About Pfizer (PFE)

Pfizer Inc. is a prominent American biopharmaceutical company founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York. The company develops, produces, and sells drugs and vaccines to treat various diseases. Pfizer is particularly well-known for its flagship products, such as Lipitor (atorvastatin) to lower cholesterol, Viagra (sildenafil) to address erectile dysfunction, and Prevenar, a pneumococcal vaccine.

In 2020, Pfizer, in collaboration with the German company BioNTech, developed Comirnaty, one of the first COVID-19 vaccines based on mRNA technology, which significantly boosted Pfizer’s global profile. The company is actively investing in research and development to expand its range of innovative medicines and solidify its position in the global pharmaceutical market.

Advantages and Disadvantages of Investing in Pfizer (PFE)

Pfizer is one of the largest pharmaceutical companies, producing popular and effective medications. Moreover, it adheres to a solid dividend policy, making the #PFE stock a safe investment option. However, like any other asset, #PFE carries not only benefits but also risks.

Advantages

• Stable pharmaceutical business. Wide range of high-demand drugs and vaccines.
• Dividend payouts. The yield is above the market average (~5%).
• Innovation leadership. Significant investments in R&D and breakthrough drugs (oncology, vaccines).
• Defensive asset. Demand for drugs remains strong even during crises.
• Global expansion. Operations in key pharmaceutical markets.
• Government support. Cooperation with regulators and research funding.
• Access to new technologies. Regular acquisitions of biotech companies.

Disadvantages

• Declining post-COVID revenues. Falling demand for vaccines and drugs used for COVID-19 treatment.
• Dependence on regulators. FDA approvals and patent litigation can impact revenue.
• Risk of patent expiration. Loss of exclusive rights reduces revenues (Lipitor is an example).
• High competition. Competing with other pharma giants for market and innovation.
• Long development cycle. Clinical tests can take years, and failures lead to significant losses.
• Sensitivity to macroeconomics. Drug price regulation, inflation.
• Stock fluctuations. Despite the stability of this field, the PFE price is susceptible to market trends.

Pfizer (PFE) is a resilient pharmaceutical company known for its solid dividends and opportunities for growth through innovation. However, investors should keep in mind that the stock price might be influenced by factors such as declining post-COVID earnings, upcoming patent expirations, and intense competition. Although the asset is suitable for long-term investments, it is essential to assess the associated risks thoroughly.

How We Make Forecasts

Stock prices are forecast based on three time frames.

• Short-term forecasts (up to 6 months) rely on technical analysis (support/resistance levels, indicators, volumes) and news. Macroeconomic events, reports, and market reactions are taken into account.
• Medium-term forecasts (from 6 months to 3 years) include fundamental analysis (financial indicators, competitive advantages, sales trends). Macroeconomic trends, interest rates, geopolitics, and the company’s product cycle are assessed.
• Long-term forecasts (3 years or more) are focused on strategic analysis. Industry potential, innovation, growth prospects, capital management, and global factors are explored. Besides, discounted cash flow (DCF) models and multiple valuations are also used.

However, each new forecast requires adjustment to align with the latest data and evolving market conditions.

Conclusion: Is Pfizer (PFE) a Good Investment?

Pfizer is a large company with an extensive product lineup, stable cash flows, and innovative technologies. However, the decision to invest depends on your financial goals and risk tolerance.

On the one hand, the company pays dividends and can increase its profits through new drugs and expansion into new markets. On the other hand, the pharmaceutical industry is highly regulated and competitive. Therefore, prior to making trading decisions, it is essential to review financial reports, company news, and expert forecasts. Those who prefer to avoid excessive risk may consider PFE as a suitable asset for a long-term portfolio.

Price chart of PFE in real time mode

Feed from Litefinance.com

MoneyMaker FX EA Trading Robot